Sorrento gets Brazilian ANVISA clearance to start Long COVID therapy trial
Sorrento Therapeutics has secured the Brazilian ANVISA authorisation to start a Phase IIa trial of COVI-MSC for treating long COVID.
Source: clinicaltrialsarena.com
Stay updated with breaking news from Drug Processing Technology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sorrento Therapeutics has secured the Brazilian ANVISA authorisation to start a Phase IIa trial of COVI-MSC for treating long COVID.
I-Mab has dosed the first subject in Phase II trial of efineptakin alfa plus pembrolizumab in advanced solid tumour patients in China.